Table II.
Correlation between FPR2 protein expression and clinicopathological characteristics of the EOC cases.
| FPR2 expression | ||||
|---|---|---|---|---|
| Variables | Cases | Positive/high (37) | Negative/low (23) | P-value |
| Age (years) | ||||
| ≥50 | 37 | 24 | 13 | 0.590 |
| <50 | 23 | 13 | 10 | |
| Histological type (carcinoma) | 0.079 | |||
| Serous | 36 | 27 | 9 | |
| Mucinous | 10 | 4 | 6 | |
| Endometrial | 7 | 3 | 4 | |
| Clear cell | 7 | 3 | 4 | |
| FIGO stage | 0.000b | |||
| I+II | 18 | 3 | 15 | |
| III+IV | 42 | 34 | 8 | |
| Histological grade | 0.000b | |||
| I+II | 26 | 9 | 17 | |
| III | 34 | 28 | 6 | |
| CA125 (U/ml) | 0.233 | |||
| >35 | 53 | 31 | 22 | |
| ≤35 | 7 | 6 | 1 | |
| Type | 0.01a | |||
| I | 19 | 7 | 12 | |
| II | 41 | 30 | 11 | |
a
P<0.05
b
P<0.01. FPR2, formyl peptide receptor 2; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics.